<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2005-06-13" updated="2020-01-02">
  <drugbank-id primary="true">DB00233</drugbank-id>
  <drugbank-id>APRD00749</drugbank-id>
  <drugbank-id>EXPT00693</drugbank-id>
  <drugbank-id>DB09367</drugbank-id>
  <name>Aminosalicylic acid</name>
  <description>An antitubercular agent often administered in association with isoniazid. The sodium salt of the drug is better tolerated than the free acid.</description>
  <cas-number>65-49-6</cas-number>
  <unii>5B2658E0N2</unii>
  <average-mass>153.1354</average-mass>
  <monoisotopic-mass>153.042593095</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
  </groups>
  <general-references>
    <articles/>
    <textbooks/>
    <links/>
    <attachments/>
  </general-references>
  <synthesis-reference>Thomas M. Parkinson, Joseph P. Brown, Robert E. Wingard, Jr., "Pharmaceutical preparations containing a polymeric agent for releasing 5-aminosalicylic acid or its salts into the gastrointestinal tract." U.S. Patent US4298595, issued January, 1975.</synthesis-reference>
  <indication>For the treatment of tuberculosis</indication>
  <pharmacodynamics>Aminosalicylic acid is an anti-mycobacterial agent used with other anti-tuberculosis drugs (most often isoniazid) for the treatment of all forms of active tuberculosis due to susceptible strains of tubercle bacilli. The two major considerations in the clinical pharmacology of aminosalicylic acid are the prompt production of a toxic inactive metabolite under acid conditions and the short serum half life of one hour for the free drug. Aminosalicylic acid is bacteriostatic against &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt; (prevents the multiplying of bacteria without destroying them). It also inhibits the onset of bacterial resistance to streptomycin and isoniazid.</pharmacodynamics>
  <mechanism-of-action>There are two mechanisms responsible for aminosalicylic acid's bacteriostatic action against &lt;i&gt;Mycobacterium tuberculosis&lt;/i&gt;. Firstly, aminosalicylic acid inhibits folic acid synthesis (without potentiation with antifolic compounds). The binding of para-aminobenzoic acid to pteridine synthetase acts as the first step in folic acid synthesis. Aminosalicylic acid binds pteridine synthetase with greater affinity than para-aminobenzoic acid, effectively inhibiting the synthesis of folic acid. As bacteria are unable to use external sources of folic acid, cell growth and multiplication slows. Secondly, aminosalicylic acid may inhibit the synthesis of the cell wall component, mycobactin, thus reducing iron uptake by &lt;i&gt;M. tuberculosis&lt;/i&gt;.</mechanism-of-action>
  <toxicity>LD&lt;sub&gt;50&lt;/sub&gt;=4 gm/kg (orally in mice); LD&lt;sub&gt;50&lt;/sub&gt;=3650 mg/kg (orally in rabbits)</toxicity>
  <metabolism>Hepatic.</metabolism>
  <absorption/>
  <half-life/>
  <protein-binding>50-60%</protein-binding>
  <route-of-elimination/>
  <volume-of-distribution/>
  <clearance/>
  <classification>
    <description>This compound belongs to the class of organic compounds known as aminosalicylic acids. These are salicylic acids carrying an amino group on the benzene ring.</description>
    <direct-parent>Aminosalicylic acids</direct-parent>
    <kingdom>Organic compounds</kingdom>
    <superclass>Benzenoids</superclass>
    <class>Benzene and substituted derivatives</class>
    <subclass>Benzoic acids and derivatives</subclass>
    <alternative-parent>1-hydroxy-2-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>1-hydroxy-4-unsubstituted benzenoids</alternative-parent>
    <alternative-parent>4-aminosalicylic acids</alternative-parent>
    <alternative-parent>Amino acids</alternative-parent>
    <alternative-parent>Aminobenzoic acids</alternative-parent>
    <alternative-parent>Aniline and substituted anilines</alternative-parent>
    <alternative-parent>Benzoic acids</alternative-parent>
    <alternative-parent>Benzoyl derivatives</alternative-parent>
    <alternative-parent>Carboxylic acids</alternative-parent>
    <alternative-parent>Hydrocarbon derivatives</alternative-parent>
    <alternative-parent>Monocarboxylic acids and derivatives</alternative-parent>
    <alternative-parent>Organic oxides</alternative-parent>
    <alternative-parent>Organooxygen compounds</alternative-parent>
    <alternative-parent>Organopnictogen compounds</alternative-parent>
    <alternative-parent>Primary amines</alternative-parent>
    <alternative-parent>Salicylic acids</alternative-parent>
    <alternative-parent>Vinylogous acids</alternative-parent>
    <alternative-parent>m-Aminophenols</alternative-parent>
    <substituent>1-hydroxy-2-unsubstituted benzenoid</substituent>
    <substituent>1-hydroxy-4-unsubstituted benzenoid</substituent>
    <substituent>4-aminosalicylic acid</substituent>
    <substituent>Amine</substituent>
    <substituent>Amino acid</substituent>
    <substituent>Amino acid or derivatives</substituent>
    <substituent>Aminobenzoic acid</substituent>
    <substituent>Aminobenzoic acid or derivatives</substituent>
    <substituent>Aminophenol</substituent>
    <substituent>Aminosalicylic acid</substituent>
    <substituent>Aniline or substituted anilines</substituent>
    <substituent>Aromatic homomonocyclic compound</substituent>
    <substituent>Benzoic acid</substituent>
    <substituent>Benzoyl</substituent>
    <substituent>Carboxylic acid</substituent>
    <substituent>Carboxylic acid derivative</substituent>
    <substituent>Hydrocarbon derivative</substituent>
    <substituent>M-aminophenol</substituent>
    <substituent>Monocarboxylic acid or derivatives</substituent>
    <substituent>Organic nitrogen compound</substituent>
    <substituent>Organic oxide</substituent>
    <substituent>Organic oxygen compound</substituent>
    <substituent>Organonitrogen compound</substituent>
    <substituent>Organooxygen compound</substituent>
    <substituent>Organopnictogen compound</substituent>
    <substituent>Phenol</substituent>
    <substituent>Primary amine</substituent>
    <substituent>Salicylic acid</substituent>
    <substituent>Vinylogous acid</substituent>
  </classification>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT001939</drugbank-id>
      <name>Aminosalicylate calcium</name>
      <unii>73I4QDW01W</unii>
      <cas-number>133-15-3</cas-number>
      <inchikey>XDWVNCOPMIEDJK-UHFFFAOYSA-L</inchikey>
      <average-mass>344.336</average-mass>
      <monoisotopic-mass>344.032127</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT000354</drugbank-id>
      <name>Aminosalicylate sodium anhydrous</name>
      <unii>T9ZKL3TNQF</unii>
      <cas-number>133-10-8</cas-number>
      <inchikey>FVVDKUPCWXUVNP-UHFFFAOYSA-M</inchikey>
      <average-mass>175.1172</average-mass>
      <monoisotopic-mass>175.024537738</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001940</drugbank-id>
      <name>Calcium aminosalicylate trihydrate</name>
      <unii>9VF16M7FWU</unii>
      <cas-number>6059-16-1</cas-number>
      <inchikey>IPLQYSPEGHNJCQ-UHFFFAOYSA-L</inchikey>
      <average-mass>398.381</average-mass>
      <monoisotopic-mass>398.0638211</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT002415</drugbank-id>
      <name>Potassium aminosalicylate</name>
      <unii>7N21461LKD</unii>
      <cas-number>133-09-5</cas-number>
      <inchikey>PRZJIMSXCLZGLT-UHFFFAOYSA-M</inchikey>
      <average-mass>191.227</average-mass>
      <monoisotopic-mass>190.99847455</monoisotopic-mass>
    </salt>
    <salt>
      <drugbank-id primary="true">DBSALT001938</drugbank-id>
      <name>Sodium aminosalicylate dihydrate</name>
      <unii>S38B9W6AXW</unii>
      <cas-number>6018-19-5</cas-number>
      <inchikey>GMUQJDAYXZXBOT-UHFFFAOYSA-M</inchikey>
      <average-mass>211.149</average-mass>
      <monoisotopic-mass>211.04566671</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="iupac">4-amino-2-hydroxybenzoic acid</synonym>
    <synonym language="english" coder="">4-aminosalicylate</synonym>
    <synonym language="english" coder="">4-aminosalicylic acid</synonym>
    <synonym language="english" coder="usp">Aminosalicylic acid</synonym>
    <synonym language="english" coder="">p-aminosalicylic acid</synonym>
    <synonym language="english" coder="">para-amino salicylic acid</synonym>
    <synonym language="english" coder="">para-aminosalicylic acid</synonym>
    <synonym language="english" coder="">PAS</synonym>
  </synonyms>
  <products>
    <product>
      <name>Granupas</name>
      <labeller>Eurocept International B. V.</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id/>
      <ema-product-code>EMEA/H/C/002709</ema-product-code>
      <ema-ma-number>EU/1/13/896/001</ema-ma-number>
      <started-marketing-on>2014-04-07</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Granule, delayed release</dosage-form>
      <strength>4 g</strength>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>EU</country>
      <source>EMA</source>
    </product>
    <product>
      <name>Nemasol Sodium Tab 500mg</name>
      <labeller>Icn Pharmaceuticals</labeller>
      <ndc-id/>
      <ndc-product-code/>
      <dpd-id>00236691</dpd-id>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1966-12-31</started-marketing-on>
      <ended-marketing-on>2005-04-26</ended-marketing-on>
      <dosage-form>Tablet</dosage-form>
      <strength/>
      <route>Oral</route>
      <fda-application-number/>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>Canada</country>
      <source>DPD</source>
    </product>
    <product>
      <name>Paser</name>
      <labeller>Jacobus Pharmaceutical</labeller>
      <ndc-id/>
      <ndc-product-code>49938-107</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>1995-02-15</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Granule, delayed release</dosage-form>
      <strength>4 g/1</strength>
      <route>Oral</route>
      <fda-application-number>ANDA074346</fda-application-number>
      <generic>true</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands>
    <international-brand>
      <name>Pamisyl</name>
      <company>Parke-Davis</company>
    </international-brand>
    <international-brand>
      <name>Rexipas</name>
      <company>Bristol-Myers Squibb</company>
    </international-brand>
    <international-brand>
      <name>Rezipas</name>
      <company>Bristol-Myers Squibb</company>
    </international-brand>
  </international-brands>
  <mixtures>
    <mixture>
      <name>Granupas</name>
      <ingredients>Aminosalicylic acid</ingredients>
    </mixture>
    <mixture>
      <name>Paser</name>
      <ingredients>Aminosalicylic acid</ingredients>
    </mixture>
    <mixture>
      <name>Nemasol Sodium Tab 500mg</name>
      <ingredients>Aminosalicylic acid</ingredients>
    </mixture>
  </mixtures>
  <packagers>
    <packager>
      <name>Jacobus Pharmaceutical Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Medisca Inc.</name>
      <url>http://www.medisca.com</url>
    </packager>
    <packager>
      <name>Professional Co.</name>
      <url/>
    </packager>
    <packager>
      <name>Spectrum Pharmaceuticals</name>
      <url>http://www.spectrumpharm.com</url>
    </packager>
  </packagers>
  <manufacturers>
    <manufacturer generic="false" url="">Century pharmaceuticals inc</manufacturer>
    <manufacturer generic="false" url="">Hexcel chemical products</manufacturer>
    <manufacturer generic="false" url="">Panray corp sub ormont drug and chemical co inc</manufacturer>
    <manufacturer generic="false" url="">Lannett co inc</manufacturer>
    <manufacturer generic="false" url="">Consolidated midland corp</manufacturer>
    <manufacturer generic="false" url="">Jacobus pharmaceutical co</manufacturer>
    <manufacturer generic="false" url="">Bristol myers squibb co</manufacturer>
  </manufacturers>
  <prices>
    <price>
      <description>Aminosalicylic acid powder</description>
      <cost currency="USD">2.4</cost>
      <unit>g</unit>
    </price>
    <price>
      <description>Paser granules 4 gm packet</description>
      <cost currency="USD">3.59</cost>
      <unit>packet</unit>
    </price>
  </prices>
  <categories>
    <category>
      <category>Acids, Carbocyclic</category>
      <mesh-id>D000146</mesh-id>
    </category>
    <category>
      <category>Aminobenzoates</category>
      <mesh-id>D062365</mesh-id>
    </category>
    <category>
      <category>Aminosalicylic Acid and Derivatives</category>
      <mesh-id/>
    </category>
    <category>
      <category>Aminosalicylic Acids</category>
      <mesh-id>D000636</mesh-id>
    </category>
    <category>
      <category>Anti-Bacterial Agents</category>
      <mesh-id>D000900</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antiinfectives for Systemic Use</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antimycobacterials</category>
      <mesh-id/>
    </category>
    <category>
      <category>Antituberculosis Agents</category>
      <mesh-id>D000995</mesh-id>
    </category>
    <category>
      <category>Benzene Derivatives</category>
      <mesh-id>D001555</mesh-id>
    </category>
    <category>
      <category>Benzoates</category>
      <mesh-id>D001565</mesh-id>
    </category>
    <category>
      <category>Drugs for Treatment of Tuberculosis</category>
      <mesh-id/>
    </category>
    <category>
      <category>Hydroxy Acids</category>
      <mesh-id>D006880</mesh-id>
    </category>
    <category>
      <category>Hydroxybenzoates</category>
      <mesh-id>D062385</mesh-id>
    </category>
    <category>
      <category>para-Aminobenzoates</category>
      <mesh-id>D062366</mesh-id>
    </category>
    <category>
      <category>Phenols</category>
      <mesh-id>D010636</mesh-id>
    </category>
    <category>
      <category>Salicylates</category>
      <mesh-id>D012459</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Mycobacteria</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Granule, delayed release</form>
      <route>Oral</route>
      <strength>4 g</strength>
    </dosage>
    <dosage>
      <form>Tablet</form>
      <route>Oral</route>
      <strength/>
    </dosage>
    <dosage>
      <form>Granule, delayed release</form>
      <route>Oral</route>
      <strength>4 g/1</strength>
    </dosage>
  </dosages>
  <atc-codes>
    <atc-code code="J04AA02">
      <level code="J04AA">Aminosalicylic acid and derivatives</level>
      <level code="J04A">DRUGS FOR TREATMENT OF TUBERCULOSIS</level>
      <level code="J04">ANTIMYCOBACTERIALS</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
    <atc-code code="J04AA03">
      <level code="J04AA">Aminosalicylic acid and derivatives</level>
      <level code="J04A">DRUGS FOR TREATMENT OF TUBERCULOSIS</level>
      <level code="J04">ANTIMYCOBACTERIALS</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
    <atc-code code="J04AA01">
      <level code="J04AA">Aminosalicylic acid and derivatives</level>
      <level code="J04A">DRUGS FOR TREATMENT OF TUBERCULOSIS</level>
      <level code="J04">ANTIMYCOBACTERIALS</level>
      <level code="J">ANTIINFECTIVES FOR SYSTEMIC USE</level>
    </atc-code>
  </atc-codes>
  <ahfs-codes/>
  <pdb-entries>
    <pdb-entry>1pbc</pdb-entry>
    <pdb-entry>1pbf</pdb-entry>
    <pdb-entry>1sxk</pdb-entry>
    <pdb-entry>5x7z</pdb-entry>
  </pdb-entries>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB00233.pdf?1265922740</msds>
  <patents/>
  <food-interactions>
    <food-interaction>Take without regard to meals.</food-interaction>
  </food-interactions>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06767</drugbank-id>
      <name>Ammonium chloride</name>
      <description>The serum concentration of Aminosalicylic acid can be increased when it is combined with Ammonium chloride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01381</drugbank-id>
      <name>Ginkgo biloba</name>
      <description>Ginkgo biloba may increase the anticoagulant activities of Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00070</drugbank-id>
      <name>Hyaluronidase (ovine)</name>
      <description>The therapeutic efficacy of Hyaluronidase (ovine) can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00563</drugbank-id>
      <name>Methotrexate</name>
      <description>The serum concentration of Methotrexate can be increased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06813</drugbank-id>
      <name>Pralatrexate</name>
      <description>The serum concentration of Pralatrexate can be increased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01032</drugbank-id>
      <name>Probenecid</name>
      <description>The therapeutic efficacy of Probenecid can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00374</drugbank-id>
      <name>Treprostinil</name>
      <description>The risk or severity of bleeding can be increased when Treprostinil is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09268</drugbank-id>
      <name>Picosulfuric acid</name>
      <description>The therapeutic efficacy of Picosulfuric acid can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01009</drugbank-id>
      <name>Ketoprofen</name>
      <description>The risk or severity of bleeding and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Ketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09214</drugbank-id>
      <name>Dexketoprofen</name>
      <description>The risk or severity of bleeding and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Dexketoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00266</drugbank-id>
      <name>Dicoumarol</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Dicoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00498</drugbank-id>
      <name>Phenindione</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Phenindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00682</drugbank-id>
      <name>Warfarin</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00946</drugbank-id>
      <name>Phenprocoumon</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Phenprocoumon.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01418</drugbank-id>
      <name>Acenocoumarol</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Acenocoumarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03410</drugbank-id>
      <name>4-hydroxycoumarin</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of 4-hydroxycoumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04665</drugbank-id>
      <name>Coumarin</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Coumarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08496</drugbank-id>
      <name>(R)-warfarin</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of (R)-warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08794</drugbank-id>
      <name>Ethyl biscoumacetate</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Ethyl biscoumacetate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13136</drugbank-id>
      <name>Fluindione</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Fluindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13275</drugbank-id>
      <name>Clorindione</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Clorindione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13347</drugbank-id>
      <name>Diphenadione</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Diphenadione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13451</drugbank-id>
      <name>Tioclomarol</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of Tioclomarol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14055</drugbank-id>
      <name>(S)-Warfarin</name>
      <description>Aminosalicylic acid may increase the anticoagulant activities of (S)-Warfarin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The serum concentration of Acetyldigitoxin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The serum concentration of Deslanoside can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The serum concentration of Ouabain can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The serum concentration of Oleandrin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The serum concentration of Cymarin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The serum concentration of Proscillaridin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The serum concentration of Lanatoside C can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The serum concentration of Gitoformate can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The serum concentration of Peruvoside can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00352</drugbank-id>
      <name>Tioguanine</name>
      <description>The metabolism of Tioguanine can be decreased when combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00993</drugbank-id>
      <name>Azathioprine</name>
      <description>The metabolism of Azathioprine can be decreased when combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01033</drugbank-id>
      <name>Mercaptopurine</name>
      <description>The metabolism of Mercaptopurine can be decreased when combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00001</drugbank-id>
      <name>Lepirudin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Lepirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00006</drugbank-id>
      <name>Bivalirudin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bivalirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00009</drugbank-id>
      <name>Alteplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Alteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00013</drugbank-id>
      <name>Urokinase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Urokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00015</drugbank-id>
      <name>Reteplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00029</drugbank-id>
      <name>Anistreplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Anistreplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00031</drugbank-id>
      <name>Tenecteplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tenecteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00054</drugbank-id>
      <name>Abciximab</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Abciximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00055</drugbank-id>
      <name>Drotrecogin alfa</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Drotrecogin alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00086</drugbank-id>
      <name>Streptokinase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Streptokinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00261</drugbank-id>
      <name>Anagrelide</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Anagrelide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00278</drugbank-id>
      <name>Argatroban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Argatroban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00407</drugbank-id>
      <name>Ardeparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ardeparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00569</drugbank-id>
      <name>Fondaparinux</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Fondaparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00686</drugbank-id>
      <name>Pentosan polysulfate</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Pentosan polysulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00975</drugbank-id>
      <name>Dipyridamole</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dipyridamole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01088</drugbank-id>
      <name>Iloprost</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Iloprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01109</drugbank-id>
      <name>Heparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Heparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01225</drugbank-id>
      <name>Enoxaparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Enoxaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01240</drugbank-id>
      <name>Epoprostenol</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Epoprostenol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04898</drugbank-id>
      <name>Ximelagatran</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ximelagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04925</drugbank-id>
      <name>Desmoteplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Desmoteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04932</drugbank-id>
      <name>Defibrotide</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Defibrotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05099</drugbank-id>
      <name>Ancrod</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ancrod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05229</drugbank-id>
      <name>Beraprost</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Beraprost.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05254</drugbank-id>
      <name>Fibrinolysin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Fibrinolysin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06209</drugbank-id>
      <name>Prasugrel</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Prasugrel.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06228</drugbank-id>
      <name>Rivaroxaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Rivaroxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06271</drugbank-id>
      <name>Sulodexide</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sulodexide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06294</drugbank-id>
      <name>Semuloparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Semuloparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06406</drugbank-id>
      <name>Idraparinux</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Idraparinux.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06441</drugbank-id>
      <name>Cangrelor</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Cangrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06543</drugbank-id>
      <name>Astaxanthin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Astaxanthin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06605</drugbank-id>
      <name>Apixaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Apixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06635</drugbank-id>
      <name>Otamixaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Otamixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06679</drugbank-id>
      <name>Amediplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Amediplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06695</drugbank-id>
      <name>Dabigatran etexilate</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran etexilate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06754</drugbank-id>
      <name>Danaparoid</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Danaparoid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06779</drugbank-id>
      <name>Dalteparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dalteparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06822</drugbank-id>
      <name>Tinzaparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tinzaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07767</drugbank-id>
      <name>Ferulic acid</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ferulic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08813</drugbank-id>
      <name>Nadroparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Nadroparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08814</drugbank-id>
      <name>Triflusal</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Triflusal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08994</drugbank-id>
      <name>Ditazole</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Ditazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09030</drugbank-id>
      <name>Vorapaxar</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Vorapaxar.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09075</drugbank-id>
      <name>Edoxaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edoxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09125</drugbank-id>
      <name>Potassium citrate</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Potassium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09154</drugbank-id>
      <name>Sodium citrate</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Sodium citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09255</drugbank-id>
      <name>Dextran</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dextran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09258</drugbank-id>
      <name>Bemiparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Bemiparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09259</drugbank-id>
      <name>Reviparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Reviparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09260</drugbank-id>
      <name>Parnaparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Parnaparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09261</drugbank-id>
      <name>Certoparin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Certoparin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11095</drugbank-id>
      <name>Desirudin</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Desirudin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11154</drugbank-id>
      <name>Zinc citrate</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Zinc citrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11166</drugbank-id>
      <name>Antithrombin Alfa</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin Alfa.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11312</drugbank-id>
      <name>Protein C</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Protein C.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11598</drugbank-id>
      <name>Antithrombin III human</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Antithrombin III human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11984</drugbank-id>
      <name>Letaxaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Letaxaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12289</drugbank-id>
      <name>Darexaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Darexaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12364</drugbank-id>
      <name>Betrixaban</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Betrixaban.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Nafamostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12726</drugbank-id>
      <name>Monteplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Monteplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12831</drugbank-id>
      <name>Gabexate</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Gabexate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13149</drugbank-id>
      <name>Protein S human</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Protein S human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13199</drugbank-id>
      <name>Brinase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Brinase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13616</drugbank-id>
      <name>Melagatran</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Melagatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13646</drugbank-id>
      <name>Saruplase</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Saruplase.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14094</drugbank-id>
      <name>Tocopherylquinone</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Tocopherylquinone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14598</drugbank-id>
      <name>Edetate calcium disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edetate calcium disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14600</drugbank-id>
      <name>Edetate disodium anhydrous</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Edetate disodium anhydrous.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14726</drugbank-id>
      <name>Dabigatran</name>
      <description>The risk or severity of bleeding can be increased when Aminosalicylic acid is combined with Dabigatran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00178</drugbank-id>
      <name>Ramipril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Ramipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00492</drugbank-id>
      <name>Fosinopril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Fosinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00519</drugbank-id>
      <name>Trandolapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Trandolapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00542</drugbank-id>
      <name>Benazepril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Benazepril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00584</drugbank-id>
      <name>Enalapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Enalapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00691</drugbank-id>
      <name>Moexipril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Moexipril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00722</drugbank-id>
      <name>Lisinopril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Lisinopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00790</drugbank-id>
      <name>Perindopril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Perindopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00881</drugbank-id>
      <name>Quinapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Quinapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00886</drugbank-id>
      <name>Omapatrilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Omapatrilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01180</drugbank-id>
      <name>Rescinnamine</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Rescinnamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01197</drugbank-id>
      <name>Captopril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Captopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01340</drugbank-id>
      <name>Cilazapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Cilazapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01348</drugbank-id>
      <name>Spirapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Spirapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08836</drugbank-id>
      <name>Temocapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Temocapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09477</drugbank-id>
      <name>Enalaprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Enalaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11783</drugbank-id>
      <name>Imidapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Imidapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13166</drugbank-id>
      <name>Zofenopril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Zofenopril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13312</drugbank-id>
      <name>Delapril</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Delapril.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14125</drugbank-id>
      <name>Benazeprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Benazeprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14207</drugbank-id>
      <name>Fosinoprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Fosinoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14208</drugbank-id>
      <name>Ramiprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Ramiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14209</drugbank-id>
      <name>Trandolaprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Trandolaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14210</drugbank-id>
      <name>Moexiprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Moexiprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14213</drugbank-id>
      <name>Perindoprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Perindoprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14217</drugbank-id>
      <name>Quinaprilat</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Quinaprilat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14231</drugbank-id>
      <name>Quinoline Yellow WS</name>
      <description>The risk or severity of renal failure can be increased when Aminosalicylic acid is combined with Quinoline Yellow WS.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00214</drugbank-id>
      <name>Torasemide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Torasemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00887</drugbank-id>
      <name>Bumetanide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Bumetanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00903</drugbank-id>
      <name>Etacrynic acid</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Etacrynic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02925</drugbank-id>
      <name>Piretanide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Piretanide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08961</drugbank-id>
      <name>Azosemide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Azosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00311</drugbank-id>
      <name>Ethoxzolamide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Ethoxzolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00703</drugbank-id>
      <name>Methazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Methazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00819</drugbank-id>
      <name>Acetazolamide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Acetazolamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00909</drugbank-id>
      <name>Zonisamide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Zonisamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01144</drugbank-id>
      <name>Diclofenamide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Diclofenamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00936</drugbank-id>
      <name>Salicylic acid</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Salicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01250</drugbank-id>
      <name>Olsalazine</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Olsalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01294</drugbank-id>
      <name>Bismuth subsalicylate</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Bismuth subsalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06251</drugbank-id>
      <name>Dersalazine</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Dersalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06807</drugbank-id>
      <name>Phenyl aminosalicylate</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Phenyl aminosalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09543</drugbank-id>
      <name>Methyl salicylate</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Methyl salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13509</drugbank-id>
      <name>Aloxiprin</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Aloxiprin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13538</drugbank-id>
      <name>Guacetisal</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Guacetisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13612</drugbank-id>
      <name>Carbaspirin calcium</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Carbaspirin calcium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Choline salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14026</drugbank-id>
      <name>Thiosalicylic acid</name>
      <description>The risk or severity of bleeding, nephrotoxicity, and gastrointestinal bleeding can be increased when Aminosalicylic acid is combined with Thiosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00313</drugbank-id>
      <name>Valproic acid</name>
      <description>The serum concentration of Valproic acid can be increased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00159</drugbank-id>
      <name>Icosapent</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Icosapent.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00244</drugbank-id>
      <name>Mesalazine</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Mesalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00328</drugbank-id>
      <name>Indomethacin</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Indomethacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00461</drugbank-id>
      <name>Nabumetone</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Nabumetone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00465</drugbank-id>
      <name>Ketorolac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Ketorolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00469</drugbank-id>
      <name>Tenoxicam</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Tenoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00500</drugbank-id>
      <name>Tolmetin</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Tolmetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00554</drugbank-id>
      <name>Piroxicam</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Piroxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00573</drugbank-id>
      <name>Fenoprofen</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Fenoprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00586</drugbank-id>
      <name>Diclofenac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Diclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00605</drugbank-id>
      <name>Sulindac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Sulindac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00712</drugbank-id>
      <name>Flurbiprofen</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Flurbiprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00749</drugbank-id>
      <name>Etodolac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Etodolac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00784</drugbank-id>
      <name>Mefenamic acid</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Mefenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00788</drugbank-id>
      <name>Naproxen</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Naproxen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00795</drugbank-id>
      <name>Sulfasalazine</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Sulfasalazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00812</drugbank-id>
      <name>Phenylbutazone</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Phenylbutazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00814</drugbank-id>
      <name>Meloxicam</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Meloxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00821</drugbank-id>
      <name>Carprofen</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Carprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00861</drugbank-id>
      <name>Diflunisal</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Diflunisal.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00870</drugbank-id>
      <name>Suprofen</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Suprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00939</drugbank-id>
      <name>Meclofenamic acid</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Meclofenamic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00945</drugbank-id>
      <name>Acetylsalicylic acid</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Acetylsalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00963</drugbank-id>
      <name>Bromfenac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Bromfenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00991</drugbank-id>
      <name>Oxaprozin</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Oxaprozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01014</drugbank-id>
      <name>Balsalazide</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Balsalazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01397</drugbank-id>
      <name>Magnesium salicylate</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Magnesium salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01399</drugbank-id>
      <name>Salsalate</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Salsalate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01401</drugbank-id>
      <name>Choline magnesium trisalicylate</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Choline magnesium trisalicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01419</drugbank-id>
      <name>Antrafenine</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Antrafenine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01600</drugbank-id>
      <name>Tiaprofenic acid</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Tiaprofenic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06725</drugbank-id>
      <name>Lornoxicam</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Lornoxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06736</drugbank-id>
      <name>Aceclofenac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Aceclofenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06802</drugbank-id>
      <name>Nepafenac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Nepafenac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09213</drugbank-id>
      <name>Dexibuprofen</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Dexibuprofen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09215</drugbank-id>
      <name>Droxicam</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Droxicam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11079</drugbank-id>
      <name>Trolamine salicylate</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Trolamine salicylate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13346</drugbank-id>
      <name>Bufexamac</name>
      <description>The therapeutic efficacy of Aminosalicylic acid can be decreased when used in combination with Bufexamac.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The risk or severity of bleeding can be increased when Diltiazem is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The risk or severity of bleeding can be increased when Verapamil is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00180</drugbank-id>
      <name>Flunisolide</name>
      <description>The serum concentration of Flunisolide can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00443</drugbank-id>
      <name>Betamethasone</name>
      <description>The serum concentration of Betamethasone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00620</drugbank-id>
      <name>Triamcinolone</name>
      <description>The serum concentration of Triamcinolone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00635</drugbank-id>
      <name>Prednisone</name>
      <description>The serum concentration of Prednisone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00687</drugbank-id>
      <name>Fludrocortisone</name>
      <description>The serum concentration of Fludrocortisone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00741</drugbank-id>
      <name>Hydrocortisone</name>
      <description>The serum concentration of Hydrocortisone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00860</drugbank-id>
      <name>Prednisolone</name>
      <description>The serum concentration of Prednisolone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00959</drugbank-id>
      <name>Methylprednisolone</name>
      <description>The serum concentration of Methylprednisolone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01108</drugbank-id>
      <name>Trilostane</name>
      <description>The serum concentration of Trilostane can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01222</drugbank-id>
      <name>Budesonide</name>
      <description>The serum concentration of Budesonide can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01234</drugbank-id>
      <name>Dexamethasone</name>
      <description>The serum concentration of Dexamethasone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01285</drugbank-id>
      <name>Corticotropin</name>
      <description>The serum concentration of Corticotropin can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01380</drugbank-id>
      <name>Cortisone acetate</name>
      <description>The serum concentration of Cortisone acetate can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01384</drugbank-id>
      <name>Paramethasone</name>
      <description>The serum concentration of Paramethasone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04630</drugbank-id>
      <name>Aldosterone</name>
      <description>The serum concentration of Aldosterone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09378</drugbank-id>
      <name>Fluprednisolone</name>
      <description>The serum concentration of Fluprednisolone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09383</drugbank-id>
      <name>Meprednisone</name>
      <description>The serum concentration of Meprednisone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11529</drugbank-id>
      <name>Melengestrol</name>
      <description>The serum concentration of Melengestrol can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11921</drugbank-id>
      <name>Deflazacort</name>
      <description>The serum concentration of Deflazacort can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13003</drugbank-id>
      <name>Cortivazol</name>
      <description>The serum concentration of Cortivazol can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13208</drugbank-id>
      <name>Prednylidene</name>
      <description>The serum concentration of Prednylidene can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13843</drugbank-id>
      <name>Cloprednol</name>
      <description>The serum concentration of Cloprednol can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14681</drugbank-id>
      <name>Cortisone</name>
      <description>The serum concentration of Cortisone can be decreased when it is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12768</drugbank-id>
      <name>BCG vaccine</name>
      <description>The therapeutic efficacy of BCG vaccine can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14022</drugbank-id>
      <name>Typhoid vaccine</name>
      <description>The therapeutic efficacy of Typhoid vaccine can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00063</drugbank-id>
      <name>Eptifibatide</name>
      <description>The risk or severity of bleeding can be increased when Eptifibatide is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The risk or severity of bleeding can be increased when Ticlopidine is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00758</drugbank-id>
      <name>Clopidogrel</name>
      <description>The risk or severity of bleeding can be increased when Clopidogrel is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00775</drugbank-id>
      <name>Tirofiban</name>
      <description>The risk or severity of bleeding can be increased when Tirofiban is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00806</drugbank-id>
      <name>Pentoxifylline</name>
      <description>The risk or severity of bleeding can be increased when Pentoxifylline is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01138</drugbank-id>
      <name>Sulfinpyrazone</name>
      <description>The risk or severity of bleeding can be increased when Sulfinpyrazone is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The risk or severity of bleeding can be increased when Cilostazol is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01207</drugbank-id>
      <name>Ridogrel</name>
      <description>The risk or severity of bleeding can be increased when Ridogrel is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01236</drugbank-id>
      <name>Sevoflurane</name>
      <description>The risk or severity of bleeding can be increased when Sevoflurane is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02709</drugbank-id>
      <name>Resveratrol</name>
      <description>The risk or severity of bleeding can be increased when Resveratrol is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04743</drugbank-id>
      <name>Nimesulide</name>
      <description>The risk or severity of bleeding can be increased when Nimesulide is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The risk or severity of bleeding can be increased when Tesmilifene is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05266</drugbank-id>
      <name>Ibudilast</name>
      <description>The risk or severity of bleeding can be increased when Ibudilast is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05767</drugbank-id>
      <name>Andrographolide</name>
      <description>The risk or severity of bleeding can be increased when Andrographolide is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06081</drugbank-id>
      <name>Caplacizumab</name>
      <description>The risk or severity of bleeding can be increased when Caplacizumab is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07615</drugbank-id>
      <name>Tranilast</name>
      <description>The risk or severity of bleeding can be increased when Tranilast is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08887</drugbank-id>
      <name>Icosapent ethyl</name>
      <description>The risk or severity of bleeding can be increased when Icosapent ethyl is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09283</drugbank-id>
      <name>Trapidil</name>
      <description>The risk or severity of bleeding can be increased when Trapidil is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12092</drugbank-id>
      <name>Naftopidil</name>
      <description>The risk or severity of bleeding can be increased when Naftopidil is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12163</drugbank-id>
      <name>Sarpogrelate</name>
      <description>The risk or severity of bleeding can be increased when Sarpogrelate is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12321</drugbank-id>
      <name>Ifetroban</name>
      <description>The risk or severity of bleeding can be increased when Ifetroban is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12445</drugbank-id>
      <name>Nitroaspirin</name>
      <description>The risk or severity of bleeding can be increased when Nitroaspirin is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12465</drugbank-id>
      <name>Ketanserin</name>
      <description>The risk or severity of bleeding can be increased when Ketanserin is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12545</drugbank-id>
      <name>Indobufen</name>
      <description>The risk or severity of bleeding can be increased when Indobufen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12749</drugbank-id>
      <name>Butylphthalide</name>
      <description>The risk or severity of bleeding can be increased when Butylphthalide is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12771</drugbank-id>
      <name>Hydroxytyrosol</name>
      <description>The risk or severity of bleeding can be increased when Hydroxytyrosol is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13036</drugbank-id>
      <name>Ramatroban</name>
      <description>The risk or severity of bleeding can be increased when Ramatroban is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13327</drugbank-id>
      <name>Picotamide</name>
      <description>The risk or severity of bleeding can be increased when Picotamide is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13367</drugbank-id>
      <name>Cloricromen</name>
      <description>The risk or severity of bleeding can be increased when Cloricromen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13400</drugbank-id>
      <name>Linsidomine</name>
      <description>The risk or severity of bleeding can be increased when Linsidomine is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13510</drugbank-id>
      <name>Buflomedil</name>
      <description>The risk or severity of bleeding can be increased when Buflomedil is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13929</drugbank-id>
      <name>Relcovaptan</name>
      <description>The risk or severity of bleeding can be increased when Relcovaptan is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10076</drugbank-id>
      <name>Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 1482 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10342</drugbank-id>
      <name>Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen</name>
      <description>The risk or severity of adverse effects can be increased when Haemophilus influenzae type B capsular polysaccharide meningococcal outer membrane protein conjugate antigen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10600</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10794</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10990</drugbank-id>
      <name>Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen</name>
      <description>The risk or severity of adverse effects can be increased when Haemophilus influenzae type B strain 20752 capsular polysaccharide tetanus toxoid conjugate antigen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11038</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11040</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11041</drugbank-id>
      <name>Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 X-181 (H1N1) hemagglutinin antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11044</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14384</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) hemagglutinin antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14385</drugbank-id>
      <name>Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza B virus B/Brisbane/60/2008 hemagglutinin antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14394</drugbank-id>
      <name>Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/California/7/2009 (H1N1) live (attenuated) antigen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14445</drugbank-id>
      <name>Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/Victoria/210/2009 X-187 (H3N2) antigen (formaldehyde inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14449</drugbank-id>
      <name>Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/Perth/16/2009 (H3N2) live (attenuated) antigen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14619</drugbank-id>
      <name>Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/Uruguay/716/2007(H3N2) antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14620</drugbank-id>
      <name>Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated)</name>
      <description>The risk or severity of adverse effects can be increased when Influenza A virus A/Brisbane/59/2007(H1N1) antigen (propiolactone inactivated) is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09413</drugbank-id>
      <name>Monopotassium phosphate</name>
      <description>The serum concentration of Aminosalicylic acid can be increased when it is combined with Monopotassium phosphate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB10318</drugbank-id>
      <name>Varicella Zoster Vaccine (Live/attenuated)</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Varicella Zoster Vaccine (Live/attenuated).</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01045</drugbank-id>
      <name>Rifampicin</name>
      <description>Aminosalicylic acid can cause a decrease in the absorption of Rifampicin resulting in a reduced serum concentration and potentially a decrease in efficacy.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00581</drugbank-id>
      <name>Lactulose</name>
      <description>The therapeutic efficacy of Lactulose can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00024</drugbank-id>
      <name>Thyrotropin alfa</name>
      <description>The therapeutic efficacy of Thyrotropin alfa can be increased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00279</drugbank-id>
      <name>Liothyronine</name>
      <description>The therapeutic efficacy of Liothyronine can be increased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00451</drugbank-id>
      <name>Levothyroxine</name>
      <description>The therapeutic efficacy of Levothyroxine can be increased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01583</drugbank-id>
      <name>Liotrix</name>
      <description>The therapeutic efficacy of Liotrix can be increased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03604</drugbank-id>
      <name>Tiratricol</name>
      <description>The therapeutic efficacy of Tiratricol can be increased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09100</drugbank-id>
      <name>Thyroid, porcine</name>
      <description>The therapeutic efficacy of Thyroid, porcine can be increased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00017</drugbank-id>
      <name>Salmon Calcitonin</name>
      <description>The therapeutic efficacy of Salmon Calcitonin can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00066</drugbank-id>
      <name>Follitropin</name>
      <description>The therapeutic efficacy of Follitropin can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00389</drugbank-id>
      <name>Carbimazole</name>
      <description>The therapeutic efficacy of Carbimazole can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00550</drugbank-id>
      <name>Propylthiouracil</name>
      <description>The therapeutic efficacy of Propylthiouracil can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The therapeutic efficacy of Methimazole can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03374</drugbank-id>
      <name>3,5-Diiodotyrosine</name>
      <description>The therapeutic efficacy of 3,5-Diiodotyrosine can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05084</drugbank-id>
      <name>Abaloparatide</name>
      <description>The therapeutic efficacy of Abaloparatide can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05829</drugbank-id>
      <name>Parathyroid hormone</name>
      <description>The therapeutic efficacy of Parathyroid hormone can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06285</drugbank-id>
      <name>Teriparatide</name>
      <description>The therapeutic efficacy of Teriparatide can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06715</drugbank-id>
      <name>Potassium Iodide</name>
      <description>The therapeutic efficacy of Potassium Iodide can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB07637</drugbank-id>
      <name>Dibromotyrosine</name>
      <description>The therapeutic efficacy of Dibromotyrosine can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09418</drugbank-id>
      <name>Potassium perchlorate</name>
      <description>The therapeutic efficacy of Potassium perchlorate can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09421</drugbank-id>
      <name>Protirelin</name>
      <description>The therapeutic efficacy of Protirelin can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12629</drugbank-id>
      <name>3,5-diiodothyropropionic acid</name>
      <description>The therapeutic efficacy of 3,5-diiodothyropropionic acid can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13644</drugbank-id>
      <name>Methylthiouracil</name>
      <description>The therapeutic efficacy of Methylthiouracil can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13742</drugbank-id>
      <name>Elcatonin</name>
      <description>The therapeutic efficacy of Elcatonin can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13804</drugbank-id>
      <name>Benzylthiouracil</name>
      <description>The therapeutic efficacy of Benzylthiouracil can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15263</drugbank-id>
      <name>Thyrotropin</name>
      <description>The therapeutic efficacy of Thyrotropin can be decreased when used in combination with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The risk or severity of adverse effects can be increased when Acetaminophen is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The risk or severity of adverse effects can be increased when Propacetamol is combined with Aminosalicylic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00695</drugbank-id>
      <name>Furosemide</name>
      <description>The risk or severity of adverse effects can be increased when Aminosalicylic acid is combined with Furosemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00030</drugbank-id>
      <name>Insulin human</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin human.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00046</drugbank-id>
      <name>Insulin lispro</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin lispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00047</drugbank-id>
      <name>Insulin glargine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin glargine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00071</drugbank-id>
      <name>Insulin pork</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin pork.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00197</drugbank-id>
      <name>Troglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Troglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00222</drugbank-id>
      <name>Glimepiride</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Glimepiride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00263</drugbank-id>
      <name>Sulfisoxazole</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Sulfisoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00280</drugbank-id>
      <name>Disopyramide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Disopyramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00284</drugbank-id>
      <name>Acarbose</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Acarbose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Metformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00359</drugbank-id>
      <name>Sulfadiazine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Sulfadiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00414</drugbank-id>
      <name>Acetohexamide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Acetohexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00491</drugbank-id>
      <name>Miglitol</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Miglitol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00672</drugbank-id>
      <name>Chlorpropamide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Chlorpropamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00839</drugbank-id>
      <name>Tolazamide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Tolazamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00912</drugbank-id>
      <name>Repaglinide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Repaglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01015</drugbank-id>
      <name>Sulfamethoxazole</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Sulfamethoxazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01016</drugbank-id>
      <name>Glyburide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Glyburide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01067</drugbank-id>
      <name>Glipizide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Glipizide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01120</drugbank-id>
      <name>Gliclazide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Gliclazide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01124</drugbank-id>
      <name>Tolbutamide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Tolbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01132</drugbank-id>
      <name>Pioglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Pioglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01200</drugbank-id>
      <name>Bromocriptine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Bromocriptine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01251</drugbank-id>
      <name>Gliquidone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Gliquidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01252</drugbank-id>
      <name>Mitiglinide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Mitiglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01261</drugbank-id>
      <name>Sitagliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Sitagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01268</drugbank-id>
      <name>Sunitinib</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Sunitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01276</drugbank-id>
      <name>Exenatide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Exenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01277</drugbank-id>
      <name>Mecasermin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Mecasermin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01278</drugbank-id>
      <name>Pramlintide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Pramlintide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01289</drugbank-id>
      <name>Glisoxepide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Glisoxepide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01306</drugbank-id>
      <name>Insulin aspart</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin aspart.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01307</drugbank-id>
      <name>Insulin detemir</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin detemir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01309</drugbank-id>
      <name>Insulin glulisine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin glulisine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01382</drugbank-id>
      <name>Glymidine</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Glymidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01700</drugbank-id>
      <name>AICA ribonucleotide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of AICA ribonucleotide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04830</drugbank-id>
      <name>Buformin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Buformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04876</drugbank-id>
      <name>Vildagliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Vildagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04878</drugbank-id>
      <name>Voglibose</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Voglibose.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05115</drugbank-id>
      <name>NN344</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of NN344.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05819</drugbank-id>
      <name>NBI-6024</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of NBI-6024.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06011</drugbank-id>
      <name>AMG-222</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of AMG-222.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06127</drugbank-id>
      <name>Bisegliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Bisegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Alogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06335</drugbank-id>
      <name>Saxagliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Saxagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06655</drugbank-id>
      <name>Liraglutide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Liraglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08382</drugbank-id>
      <name>Gosogliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Gosogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Linagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08907</drugbank-id>
      <name>Canagliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Canagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08962</drugbank-id>
      <name>Glibornuride</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Glibornuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09022</drugbank-id>
      <name>Benfluorex</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Benfluorex.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09038</drugbank-id>
      <name>Empagliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Empagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09043</drugbank-id>
      <name>Albiglutide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Albiglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09045</drugbank-id>
      <name>Dulaglutide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Dulaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09198</drugbank-id>
      <name>Lobeglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Lobeglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09199</drugbank-id>
      <name>Netoglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Netoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09200</drugbank-id>
      <name>Rivoglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Rivoglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09201</drugbank-id>
      <name>Ciglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Ciglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09265</drugbank-id>
      <name>Lixisenatide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Lixisenatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09456</drugbank-id>
      <name>Insulin beef</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin beef.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09564</drugbank-id>
      <name>Insulin degludec</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin degludec.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11567</drugbank-id>
      <name>Insulin peglispro</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin peglispro.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11568</drugbank-id>
      <name>Insulin tregopil</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Insulin tregopil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11698</drugbank-id>
      <name>Ipragliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Ipragliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11723</drugbank-id>
      <name>Dutogliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Dutogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11780</drugbank-id>
      <name>Allicin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Allicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11824</drugbank-id>
      <name>Tofogliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Tofogliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11827</drugbank-id>
      <name>Ertugliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Ertugliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11898</drugbank-id>
      <name>2,4-thiazolidinedione</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of 2,4-thiazolidinedione.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11936</drugbank-id>
      <name>Bempedoic acid</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Bempedoic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11950</drugbank-id>
      <name>Teneligliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Teneligliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11992</drugbank-id>
      <name>Omarigliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Omarigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12268</drugbank-id>
      <name>Carmegliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Carmegliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12412</drugbank-id>
      <name>Gemigliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Gemigliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12417</drugbank-id>
      <name>Anagliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Anagliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12625</drugbank-id>
      <name>Evogliptin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Evogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12713</drugbank-id>
      <name>Sotagliflozin</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Sotagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12781</drugbank-id>
      <name>Balaglitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Balaglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12935</drugbank-id>
      <name>Remogliflozin etabonate</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Remogliflozin etabonate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13406</drugbank-id>
      <name>Carbutamide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Carbutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13446</drugbank-id>
      <name>Guar gum</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Guar gum.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13675</drugbank-id>
      <name>Metahexamide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Metahexamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13928</drugbank-id>
      <name>Semaglutide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Semaglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14027</drugbank-id>
      <name>Taspoglutide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Taspoglutide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14035</drugbank-id>
      <name>Englitazone</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Englitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15171</drugbank-id>
      <name>Tirzepatide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Tirzepatide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15217</drugbank-id>
      <name>Gastric inhibitory polypeptide</name>
      <description>Aminosalicylic acid may increase the hypoglycemic activities of Gastric inhibitory polypeptide.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>0.62</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-1.1</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.18e+01 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.83</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>4-amino-2-hydroxybenzoic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>aminosalicylic acid</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>153.1354</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>153.042593095</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>NC1=CC(O)=C(C=C1)C(O)=O</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C7H7NO3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C7H7NO3/c8-4-1-2-5(7(10)11)6(9)3-4/h1-3,9H,8H2,(H,10,11)</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>WUBBRNOQWQTFEX-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>83.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>40</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>14.29</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>4</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>3.68</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>2.19</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>-1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>0</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>1690 mg/L (at 23 °C)</value>
      <source>YALKOWSKY,SH &amp; DANNENFELSER,RM (1992)</source>
    </property>
    <property>
      <kind>Melting Point</kind>
      <value>150.5 dec °C</value>
      <source>PhysProp</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>0.89</value>
      <source>SANGSTER (1994)</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>2.05 (at 25 °C)</value>
      <source>KORTUM,G ET AL (1961)</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>Drugs Product Database (DPD)</resource>
      <identifier>6620</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>27565</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Compound</resource>
      <identifier>4649</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PubChem Substance</resource>
      <identifier>46505572</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Compound</resource>
      <identifier>C02518</identifier>
    </external-identifier>
    <external-identifier>
      <resource>KEGG Drug</resource>
      <identifier>D00162</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>4488</identifier>
    </external-identifier>
    <external-identifier>
      <resource>BindingDB</resource>
      <identifier>48319</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA448382</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PDB</resource>
      <identifier>BHA</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>4-Aminosalicylic_acid</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL1169</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links>
    <external-link>
      <resource>RxList</resource>
      <url>http://www.rxlist.com/cgi/generic2/paser.htm</url>
    </external-link>
    <external-link>
      <resource>Drugs.com</resource>
      <url>http://www.drugs.com/cdi/aminosalicylic-acid-controlled-release-granules-packet.html</url>
    </external-link>
  </external-links>
  <pathways/>
  <reactions/>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets>
    <target position="1">
      <id>BE0000262</id>
      <name>Prostaglandin G/H synthase 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A10315</ref-id>
            <pubmed-id>14742690</pubmed-id>
            <citation>Mifflin RC, Saada JI, Di Mari JF, Valentich JD, Adegboyega PA, Powell DW: Aspirin-mediated COX-2 transcript stabilization via sustained p38 activation in human intestinal myofibroblasts. Mol Pharmacol. 2004 Feb;65(2):470-8.</citation>
          </article>
          <article>
            <ref-id>A10316</ref-id>
            <pubmed-id>12463455</pubmed-id>
            <citation>Generini S, Fiori G, Matucci Cerinic M: Therapy of spondylarthropathy in inflammatory bowel disease. Clin Exp Rheumatol. 2002 Nov-Dec;20(6 Suppl 28):S88-94.</citation>
          </article>
          <article>
            <ref-id>A10317</ref-id>
            <pubmed-id>16855178</pubmed-id>
            <citation>Distrutti E, Sediari L, Mencarelli A, Renga B, Orlandi S, Russo G, Caliendo G, Santagada V, Cirino G, Wallace JL, Fiorucci S: 5-Amino-2-hydroxybenzoic acid 4-(5-thioxo-5H-[1,2]dithiol-3yl)-phenyl ester (ATB-429), a hydrogen sulfide-releasing derivative of mesalamine, exerts antinociceptive effects in a model of postinflammatory hypersensitivity. J Pharmacol Exp Ther. 2006 Oct;319(1):447-58. Epub 2006 Jul 19.</citation>
          </article>
          <article>
            <ref-id>A10318</ref-id>
            <pubmed-id>12208114</pubmed-id>
            <citation>Cipolla G, Crema F, Sacco S, Moro E, de Ponti F, Frigo G: Nonsteroidal anti-inflammatory drugs and inflammatory bowel disease: current perspectives. Pharmacol Res. 2002 Jul;46(1):1-6.</citation>
          </article>
          <article>
            <ref-id>A10319</ref-id>
            <pubmed-id>9256165</pubmed-id>
            <citation>Pruzanski W, Stefanski E, Vadas P, Ramamurthy NS: Inhibition of extracellular release of proinflammatory secretory phospholipase A2 (sPLA2) by sulfasalazine: a novel mechanism of anti-inflammatory activity. Biochem Pharmacol. 1997 Jun 15;53(12):1901-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P35354" source="Swiss-Prot">
        <name>Prostaglandin G/H synthase 2</name>
        <general-function>Prostaglandin-endoperoxide synthase activity</general-function>
        <specific-function>Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Constitutively expressed in some tissues in physiological conditions, such as the endothelium, kidney and brain, and in pathological conditions, such as in cancer. PTGS2 is responsible for production of inflammatory prostaglandins. Up-regulation of PTGS2 is also associated with increased cell adhesion, phenotypic changes, resistance to apoptosis and tumor angiogenesis. In cancer cells, PTGS2 is a key step in the production of prostaglandin E2 (PGE2), which plays important roles in modulating motility, proliferation and resistance to apoptosis.</specific-function>
        <gene-name>PTGS2</gene-name>
        <locus>1q25.2-q25.3</locus>
        <cellular-location>Microsome membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-17</signal-regions>
        <theoretical-pi>7.41</theoretical-pi>
        <molecular-weight>68995.625</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:9605</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>PTGS2</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>L15326</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>291988</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1376</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P35354</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PGH2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.99.1</synonym>
          <synonym>COX-2</synonym>
          <synonym>COX2</synonym>
          <synonym>Cyclooxygenase-2</synonym>
          <synonym>PGH synthase 2</synonym>
          <synonym>PGHS-2</synonym>
          <synonym>PHS II</synonym>
          <synonym>Prostaglandin H2 synthase 2</synonym>
          <synonym>Prostaglandin-endoperoxide synthase 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0021832|Prostaglandin G/H synthase 2
MLARALLLCAVLALSHTANPCCSHPCQNRGVCMSVGFDQYKCDCTRTGFYGENCSTPEFL
TRIKLFLKPTPNTVHYILTHFKGFWNVVNNIPFLRNAIMSYVLTSRSHLIDSPPTYNADY
GYKSWEAFSNLSYYTRALPPVPDDCPTPLGVKGKKQLPDSNEIVEKLLLRRKFIPDPQGS
NMMFAFFAQHFTHQFFKTDHKRGPAFTNGLGHGVDLNHIYGETLARQRKLRLFKDGKMKY
QIIDGEMYPPTVKDTQAEMIYPPQVPEHLRFAVGQEVFGLVPGLMMYATIWLREHNRVCD
VLKQEHPEWGDEQLFQTSRLILIGETIKIVIEDYVQHLSGYHFKLKFDPELLFNKQFQYQ
NRIAAEFNTLYHWHPLLPDTFQIHDQKYNYQQFIYNNSILLEHGITQFVESFTRQIAGRV
AGGRNVPPAVQKVSQASIDQSRQMKYQSFNEYRKRFMLKPYESFEELTGEKEMSAELEAL
YGDIDAVELYPALLVEKPRPDAIFGETMVEVGAPFSLKGLMGNVICSPAYWKPSTFGGEV
GFQIINTASIQSLICNNVKGCPFTSFSVPDPELIKTVTINASSSRSGLDDINPTVLLKER
STEL</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021833|Prostaglandin G/H synthase 2 (PTGS2)
ATGCTCGCCCGCGCCCTGCTGCTGTGCGCGGTCCTGGCGCTCAGCCATACAGCAAATCCT
TGCTGTTCCCACCCATGTCAAAACCGAGGTGTATGTATGAGTGTGGGATTTGACCAGTAT
AAGTGCGATTGTACCCGGACAGGATTCTATGGAGAAAACTGCTCAACACCGGAATTTTTG
ACAAGAATAAAATTATTTCTGAAACCCACTCCAAACACAGTGCACTACATACTTACCCAC
TTCAAGGGATTTTGGAACGTTGTGAATAACATTCCCTTCCTTCGAAATGCAATTATGAGT
TATGTGTTGACATCCAGATCACATTTGATTGACAGTCCACCAACTTACAATGCTGACTAT
GGCTACAAAAGCTGGGAAGCCTTCTCTAACCTCTCCTATTATACTAGAGCCCTTCCTCCT
GTGCCTGATGATTGCCCGACTCCCTTGGGTGTCAAAGGTAAAAAGCAGCTTCCTGATTCA
AATGAGATTGTGGAAAAATTGCTTCTAAGAAGAAAGTTCATCCCTGATCCCCAGGGCTCA
AACATGATGTTTGCATTCTTTGCCCAGCACTTCACGCATCAGTTTTTCAAGACAGATCAT
AAGCGAGGGCCAGCTTTCACCAACGGGCTGGGCCATGGGGTGGACTTAAATCATATTTAC
GGTGAAACTCTGGCTAGACAGCGTAAACTGCGCCTTTTCAAGGATGGAAAAATGAAATAT
CAGATAATTGATGGAGAGATGTATCCTCCCACAGTCAAAGATACTCAGGCAGAGATGATC
TACCCTCCTCAAGTCCCTGAGCATCTACGGTTTGCTGTGGGGCAGGAGGTCTTTGGTCTG
GTGCCTGGTCTGATGATGTATGCCACAATCTGGCTGCGGGAACACAACAGAGTATGCGAT
GTGCTTAAACAGGAGCATCCTGAATGGGGTGATGAGCAGTTGTTCCAGACAAGCAGGCTA
ATACTGATAGGAGAGACTATTAAGATTGTGATTGAAGATTATGTGCAACACTTGAGTGGC
TATCACTTCAAACTGAAATTTGACCCAGAACTACTTTTCAACAAACAATTCCAGTACCAA
AATCGTATTGCTGCTGAATTTAACACCCTCTATCACTGGCATCCCCTTCTGCCTGACACC
TTTCAAATTCATGACCAGAAATACAACTATCAACAGTTTATCTACAACAACTCTATATTG
CTGGAACATGGAATTACCCAGTTTGTTGAATCATTCACCAGGCAAATTGCTGGCAGGGTT
GCTGGTGGTAGGAATGTTCCACCCGCAGTACAGAAAGTATCACAGGCTTCCATTGACCAG
AGCAGGCAGATGAAATACCAGTCTTTTAATGAGTACCGCAAACGCTTTATGCTGAAGCCC
TATGAATCATTTGAAGAACTTACAGGAGAAAAGGAAATGTCTGCAGAGTTGGAAGCACTC
TATGGTGACATCGATGCTGTGGAGCTGTATCCTGCCCTTCTGGTAGAAAAGCCTCGGCCA
GATGCCATCTTTGGTGAAACCATGGTAGAAGTTGGAGCACCATTCTCCTTGAAAGGACTT
ATGGGTAATGTTATATGTTCTCCTGCCTACTGGAAGCCAAGCACTTTTGGTGGAGAAGTG
GGTTTTCAAATCATCAACACTGCCTCAATTCAGTCTCTCATCTGCAATAACGTGAAGGGC
TGTCCCTTTACTTCATTCAGTGTTCCAGATCCAGAGCTCATTAAAACAGTCACCATCAAT
GCAAGTTCTTCCCGCTCCGGACTAGATGATATCAATCCCACAGTACTACTAAAAGAACGT
TCGACTGAACTGTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03098</identifier>
            <name>An_peroxidase</name>
          </pfam>
          <pfam>
            <identifier>PF00008</identifier>
            <name>EGF</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>caveola</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>neuron projection</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>protein complex</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonate 15-lipoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>enzyme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>lipid binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peroxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>prostaglandin-endoperoxide synthase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>bone mineralization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to ATP</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to fluid shear stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to hypoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to mechanical stimulus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to UV</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cyclooxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>decidualization</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>embryo implantation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hair cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>learning</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>maintenance of blood-brain barrier</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>memory</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>movement of cell or subcellular component</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>NAD metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of calcium ion transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell cycle</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of synaptic transmission, dopaminergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nicotinamide metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ovulation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of brown fat cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of cell migration involved in sprouting angiogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fever generation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of fibroblast growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB import into nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of nitric oxide biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of platelet-derived growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of prostaglandin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of smooth muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic plasticity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of synaptic transmission, glutamatergic</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transforming growth factor beta production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vascular endothelial growth factor production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>prostaglandin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of blood pressure</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to estradiol</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fatty acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to fructose</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to glucocorticoid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lithium ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to manganese ion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to tumor necrosis factor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to vitamin D</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>vitamin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>water-soluble vitamin metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="2">
      <id>BE0004655</id>
      <name>Inhibitor of nuclear factor kappa-B kinase subunit alpha</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16800</ref-id>
            <pubmed-id>11151876</pubmed-id>
            <citation>Bantel H, Berg C, Vieth M, Stolte M, Kruis W, Schulze-Osthoff K: Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol. 2000 Dec;95(12):3452-7.</citation>
          </article>
          <article>
            <ref-id>A4391</ref-id>
            <pubmed-id>12950415</pubmed-id>
            <citation>Allgayer H: Review article: mechanisms of action of mesalazine in preventing colorectal carcinoma in inflammatory bowel disease. Aliment Pharmacol Ther. 2003 Sep;18 Suppl 2:10-4.</citation>
          </article>
          <article>
            <ref-id>A16799</ref-id>
            <pubmed-id>11054378</pubmed-id>
            <citation>Weber CK, Liptay S, Wirth T, Adler G, Schmid RM: Suppression of NF-kappaB activity by sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. Gastroenterology. 2000 Nov;119(5):1209-18.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="O15111" source="Swiss-Prot">
        <name>Inhibitor of nuclear factor kappa-B kinase subunit alpha</name>
        <general-function>Scaffold protein binding</general-function>
        <specific-function>Serine kinase that plays an essential role in the NF-kappa-B signaling pathway which is activated by multiple stimuli such as inflammatory cytokines, bacterial or viral products, DNA damages or other cellular stresses. Acts as part of the canonical IKK complex in the conventional pathway of NF-kappa-B activation and phosphorylates inhibitors of NF-kappa-B on serine residues. These modifications allow polyubiquitination of the inhibitors and subsequent degradation by the proteasome. In turn, free NF-kappa-B is translocated into the nucleus and activates the transcription of hundreds of genes involved in immune response, growth control, or protection against apoptosis. Negatively regulates the pathway by phosphorylating the scaffold protein TAXBP1 and thus promoting the assembly of the A20/TNFAIP3 ubiquitin-editing complex (composed of A20/TNFAIP3, TAX1BP1, and the E3 ligases ITCH and RNF11). Therefore, CHUK plays a key role in the negative feedback of NF-kappa-B canonical signaling to limit inflammatory gene activation. As part of the non-canonical pathway of NF-kappa-B activation, the MAP3K14-activated CHUK/IKKA homodimer phosphorylates NFKB2/p100 associated with RelB, inducing its proteolytic processing to NFKB2/p52 and the formation of NF-kappa-B RelB-p52 complexes. In turn, these complexes regulate genes encoding molecules involved in B-cell survival and lymphoid organogenesis. Participates also in the negative feedback of the non-canonical NF-kappa-B signaling pathway by phosphorylating and destabilizing MAP3K14/NIK. Within the nucleus, phosphorylates CREBBP and consequently increases both its transcriptional and histone acetyltransferase activities. Modulates chromatin accessibility at NF-kappa-B-responsive promoters by phosphorylating histones H3 at 'Ser-10' that are subsequently acetylated at 'Lys-14' by CREBBP. Additionally, phosphorylates the CREBBP-interacting protein NCOA3. Also phosphorylates FOXO3 and may regulate this pro-apoptotic transcription factor (PubMed:15084260).</specific-function>
        <gene-name>CHUK</gene-name>
        <locus/>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>84638.88</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:1974</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1989</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15111</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>IKKA_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.11.10</synonym>
          <synonym>Conserved helix-loop-helix ubiquitous kinase</synonym>
          <synonym>I-kappa-B kinase 1</synonym>
          <synonym>I-kappa-B kinase alpha</synonym>
          <synonym>IKK1</synonym>
          <synonym>IKKA</synonym>
          <synonym>NFKBIKA</synonym>
          <synonym>Nuclear factor NF-kappa-B inhibitor kinase alpha</synonym>
          <synonym>TCF-16</synonym>
          <synonym>TCF16</synonym>
          <synonym>Transcription factor 16</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0013242|Inhibitor of nuclear factor kappa-B kinase subunit alpha
MERPPGLRPGAGGPWEMRERLGTGGFGNVCLYQHRELDLKIAIKSCRLELSTKNRERWCH
EIQIMKKLNHANVVKACDVPEELNILIHDVPLLAMEYCSGGDLRKLLNKPENCCGLKESQ
ILSLLSDIGSGIRYLHENKIIHRDLKPENIVLQDVGGKIIHKIIDLGYAKDVDQGSLCTS
FVGTLQYLAPELFENKPYTATVDYWSFGTMVFECIAGYRPFLHHLQPFTWHEKIKKKDPK
CIFACEEMSGEVRFSSHLPQPNSLCSLVVEPMENWLQLMLNWDPQQRGGPVDLTLKQPRC
FVLMDHILNLKIVHILNMTSAKIISFLLPPDESLHSLQSRIERETGINTGSQELLSETGI
SLDPRKPASQCVLDGVRGCDSYMVYLFDKSKTVYEGPFASRSLSDCVNYIVQDSKIQLPI
IQLRKVWAEAVHYVSGLKEDYSRLFQGQRAAMLSLLRYNANLTKMKNTLISASQQLKAKL
EFFHKSIQLDLERYSEQMTYGISSEKMLKAWKEMEEKAIHYAEVGVIGYLEDQIMSLHAE
IMELQKSPYGRRQGDLMESLEQRAIDLYKQLKHRPSDHSYSDSTEMVKIIVHTVQSQDRV
LKELFGHLSKLLGCKQKIIDLLPKVEVALSNIKEADNTVMFMQGKRQKEIWHLLKIACTQ
SSARSLVGSSLEGAVTPQTSAWLPPTSAEHDHSLSCVVTPQDGETSAQMIEENLNCLGHL
STIIHEANEEQGNSMMNLDWSWLTE</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0013243|Inhibitor of nuclear factor kappa-B kinase subunit alpha (CHUK)
ATGGAGCGGCCCCCGGGGCTGCGGCCGGGCGCGGGCGGGCCCTGGGAGATGCGGGAGCGG
CTGGGCACCGGCGGCTTCGGGAACGTCTGTCTGTACCAGCATCGGGAACTTGATCTCAAA
ATAGCAATTAAGTCTTGTCGCCTAGAGCTAAGTACCAAAAACAGAGAACGATGGTGCCAT
GAAATCCAGATTATGAAGAAGTTGAACCATGCCAATGTTGTAAAGGCCTGTGATGTTCCT
GAAGAATTGAATATTTTGATTCATGATGTGCCTCTTCTAGCAATGGAATACTGTTCTGGA
GGAGATCTCCGAAAGCTGCTCAACAAACCAGAAAATTGTTGTGGACTTAAAGAAAGCCAG
ATACTTTCTTTACTAAGTGATATAGGGTCTGGGATTCGATATTTGCATGAAAACAAAATT
ATACATCGAGATCTAAAACCTGAAAACATAGTTCTTCAGGATGTTGGTGGAAAGATAATA
CATAAAATAATTGATCTGGGATATGCCAAAGATGTTGATCAAGGAAGTCTGTGTACATCT
TTTGTGGGAACACTGCAGTATCTGGCCCCAGAGCTCTTTGAGAATAAGCCTTACACAGCC
ACTGTTGATTATTGGAGCTTTGGGACCATGGTATTTGAATGTATTGCTGGATATAGGCCT
TTTTTGCATCATCTGCAGCCATTTACCTGGCATGAGAAGATTAAGAAGAAGGATCCAAAG
TGTATATTTGCATGTGAAGAGATGTCAGGAGAAGTTCGGTTTAGTAGCCATTTACCTCAA
CCAAATAGCCTTTGTAGTTTAGTAGTAGAACCCATGGAAAACTGGCTACAGTTGATGTTG
AATTGGGACCCTCAGCAGAGAGGAGGACCTGTTGACCTTACTTTGAAGCAGCCAAGATGT
TTTGTATTAATGGATCACATTTTGAATTTGAAGATAGTACACATCCTAAATATGACTTCT
GCAAAGATAATTTCTTTTCTGTTACCACCTGATGAAAGTCTTCATTCACTACAGTCTCGT
ATTGAGCGTGAAACTGGAATAAATACTGGTTCTCAAGAACTTCTTTCAGAGACAGGAATT
TCTCTGGATCCTCGGAAACCAGCCTCTCAATGTGTTCTAGATGGAGTTAGAGGCTGTGAT
AGCTATATGGTTTATTTGTTTGATAAAAGTAAAACTGTATATGAAGGGCCATTTGCTTCC
AGAAGTTTATCTGATTGTGTAAATTATATTGTACAGGACAGCAAAATACAGCTTCCAATT
ATACAGCTGCGTAAAGTGTGGGCTGAAGCAGTGCACTATGTGTCTGGACTAAAAGAAGAC
TATAGCAGGCTCTTTCAGGGACAAAGGGCAGCAATGTTAAGTCTTCTTAGATATAATGCT
AACTTAACAAAAATGAAGAACACTTTGATCTCAGCATCACAACAACTGAAAGCTAAATTG
GAGTTTTTTCACAAAAGCATTCAGCTTGACTTGGAGAGATACAGCGAGCAGATGACGTAT
GGGATATCTTCAGAAAAAATGCTAAAAGCATGGAAAGAAATGGAAGAAAAGGCCATCCAC
TATGCTGAGGTTGGTGTCATTGGATACCTGGAGGATCAGATTATGTCTTTGCATGCTGAA
ATCATGGAGCTACAGAAGAGCCCCTATGGAAGACGTCAGGGAGACTTGATGGAATCTCTG
GAACAGCGTGCCATTGATCTATATAAGCAGTTAAAACACAGACCTTCAGATCACTCCTAC
AGTGACAGCACAGAGATGGTGAAAATCATTGTGCACACTGTGCAGAGTCAGGACCGTGTG
CTCAAGGAGCTGTTTGGTCATTTGAGCAAGTTGTTGGGCTGTAAGCAGAAGATTATTGAT
CTACTCCCTAAGGTGGAAGTGGCCCTCAGTAATATCAAAGAAGCTGACAATACTGTCATG
TTCATGCAGGGAAAAAGGCAGAAAGAAATATGGCATCTCCTTAAAATTGCCTGTACACAG
AGTTCTGCCCGGTCCCTTGTAGGATCCAGTCTAGAAGGTGCAGTAACCCCTCAGACATCA
GCATGGCTGCCCCCGACTTCAGCAGAACATGATCATTCTCTGTCATGTGTGGTAACTCCT
CAAGATGGGGAGACTTCAGCACAAATGATAGAAGAAAATTTGAACTGCCTTGGCCATTTA
AGCACTATTATTCATGAGGCAAATGAGGAACAGGGCAATAGTATGATGAATCTTGATTGG
AGTTGGTTAACAGAATGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00069</identifier>
            <name>Pkinase</name>
          </pfam>
          <pfam>
            <identifier>PF12179</identifier>
            <name>IKKbetaNEMObind</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>CD40 receptor complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytoplasmic side of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>IkappaB kinase complex</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>intracellular membrane-bounded organelle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>IkappaB kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein heterodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein homodimerization activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>protein kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>scaffold protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>anatomical structure morphogenesis</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cell surface receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>cellular response to tumor necrosis factor</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>epidermal growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Fc-epsilon receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>fibroblast growth factor receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>I-kappaB phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>innate immune response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lactation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland alveolus development</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>mammary gland epithelial cell proliferation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>morphogenesis of an epithelial sheet</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>MyD88-independent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotrophin TRK receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>NIK/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-binding domain, leucine rich repeat containing receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>nucleotide-binding oligomerization domain containing signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>odontogenesis of dentin-containing tooth</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>osteoclast differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol-mediated signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of I-kappaB kinase/NF-kappaB signaling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of NF-kappaB transcription factor activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of transcription from RNA polymerase II promoter</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of type I interferon production</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>protein phosphorylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>regulation of tumor necrosis factor-mediated signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to acetate</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to amino acid</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to drug</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hydroperoxide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to lipopolysaccharide</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to muscle stretch</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to toxic substance</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to virus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>Rho protein signal transduction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>skeletal muscle contraction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stimulatory C-type lectin receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>stress-activated MAPK cascade</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>striated muscle cell differentiation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>T cell receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 10 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 2 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 3 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 4 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 5 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor 9 signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR1</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>toll-like receptor TLR6</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>TRIF-dependent toll-like receptor signaling pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tumor necrosis factor-mediated signaling pathway</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="3">
      <id>BE0000248</id>
      <name>Arachidonate 5-lipoxygenase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A16801</ref-id>
            <pubmed-id>2882965</pubmed-id>
            <citation>Nielsen OH, Bukhave K, Elmgreen J, Ahnfelt-Ronne I: Inhibition of 5-lipoxygenase pathway of arachidonic acid metabolism in human neutrophils by sulfasalazine and 5-aminosalicylic acid. Dig Dis Sci. 1987 Jun;32(6):577-82.</citation>
          </article>
          <article>
            <ref-id>A16802</ref-id>
            <pubmed-id>6428914</pubmed-id>
            <citation>Allgayer H, Eisenburg J, Paumgartner G: Soybean lipoxygenase inhibition: studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine. Eur J Clin Pharmacol. 1984;26(4):449-51.</citation>
          </article>
          <article>
            <ref-id>A16803</ref-id>
            <pubmed-id>6131674</pubmed-id>
            <citation>Sircar JC, Schwender CF, Carethers ME: Inhibition of soybean lipoxygenase by sulfasalazine and 5-aminosalicylic acid: a possible mode of action in ulcerative colitis. Biochem Pharmacol. 1983 Jan 1;32(1):170-2.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P09917" source="Swiss-Prot">
        <name>Arachidonate 5-lipoxygenase</name>
        <general-function>Iron ion binding</general-function>
        <specific-function>Catalyzes the first step in leukotriene biosynthesis, and thereby plays a role in inflammatory processes.</specific-function>
        <gene-name>ALOX5</gene-name>
        <locus>10q11.2</locus>
        <cellular-location>Cytoplasm</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>5.54</theoretical-pi>
        <molecular-weight>77982.595</molecular-weight>
        <chromosome-location>10</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:435</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>ALOX5</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J03600</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>187193</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1385</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P09917</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>LOX5_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.13.11.34</synonym>
          <synonym>5-LO</synonym>
          <synonym>LOG5</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0036979|Arachidonate 5-lipoxygenase
MPSYTVTVATGSQWFAGTDDYIYLSLVGSAGCSEKHLLDKPFYNDFERGAVDSYDVTVDE
ELGEIQLVRIEKRKYWLNDDWYLKYITLKTPHGDYIEFPCYRWITGDVEVVLRDGRAKLA
RDDQIHILKQHRRKELETRQKQYRWMEWNPGFPLSIDAKCHKDLPRDIQFDSEKGVDFVL
NYSKAMENLFINRFMHMFQSSWNDFADFEKIFVKISNTISERVMNHWQEDLMFGYQFLNG
CNPVLIRRCTELPEKLPVTTEMVECSLERQLSLEQEVQQGNIFIVDFELLDGIDANKTDP
CTLQFLAAPICLLYKNLANKIVPIAIQLNQIPGDENPIFLPSDAKYDWLLAKIWVRSSDF
HVHQTITHLLRTHLVSEVFGIAMYRQLPAVHPIFKLLVAHVRFTIAINTKAREQLICECG
LFDKANATGGGGHVQMVQRAMKDLTYASLCFPEAIKARGMESKEDIPYYFYRDDGLLVWE
AIRTFTAEVVDIYYEGDQVVEEDPELQDFVNDVYVYGMRGRKSSGFPKSVKSREQLSEYL
TVVIFTASAQHAAVNFGQYDWCSWIPNAPPTMRAPPPTAKGVVTIEQIVDTLPDRGRSCW
HLGAVWALSQFQENELFLGMYPEEHFIEKPVKEAMARFRKNLEAIVSVIAERNKKKQLPY
YYLSPDRIPNSVAI</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0010032|Arachidonate 5-lipoxygenase (ALOX5)
ATGCCCTCCTACACGGTCACCGTGGCCACTGGCAGCCAGTGGTTCGCCGGCACTGACGAC
TACATCTACCTCAGCCTCGTGGGCTCGGCGGGCTGCAGCGAGAAGCACCTGCTGGACAAG
CCCTTCTACAACGACTTCGAGCGTGGCGCGGTGGATTCATACGACGTGACTGTGGACGAG
GAACTGGGCGAGATCCAGCTGGTCAGAATCGAGAAGCGCAAGTACTGGCTGAATGACGAC
TGGTACCTGAAGTACATCACGCTGAAGACGCCCCACGGGGACTACATCGAGTTCCCCTGC
TACCGCTGGATCACCGGCGATGTCGAGGTTGTCCTGAGGGATGGACGCGCAAAGTTGGCC
CGAGATGACCAAATTCACATTCTCAAGCAACACCGACGTAAAGAACTGGAAACACGGCAA
AAACAATATCGATGGATGGAGTGGAACCCTGGCTTCCCCTTGAGCATCGATGCCAAATGC
CACAAGGATTTACCCCGTGATATCCAGTTTGATAGTGAAAAAGGAGTGGACTTTGTTCTG
AATTACTCCAAAGCGATGGAGAACCTGTTCATCAACCGCTTCATGCACATGTTCCAGTCT
TCTTGGAATGACTTCGCCGACTTTGAGAAAATCTTTGTCAAGATCAGCAACACTATTTCT
GAGCGGGTCATGAATCACTGGCAGGAAGACCTGATGTTTGGCTACCAGTTCCTGAATGGC
TGCAACCCTGTGTTGATCCGGCGCTGCACAGAGCTGCCCGAGAAGCTCCCGGTGACCACG
GAGATGGTAGAGTGCAGCCTGGAGCGGCAGCTCAGCTTGGAGCAGGAGGTCCAGCAAGGG
AACATTTTCATCGTGGACTTTGAGCTGCTGGATGGCATCGATGCCAACAAAACAGACCCC
TGCACACTCCAGTTCCTGGCCGCTCCCATCTGCTTGCTGTATAAGAACCTGGCCAACAAG
ATTGTCCCCATTGCCATCCAGCTCAACCAAATCCCGGGAGATGAGAACCCTATTTTCCTC
CCTTCGGATGCAAAATACGACTGGCTTTTGGCCAAAATCTGGGTGCGTTCCAGTGACTTC
CACGTCCACCAGACCATCACCCACCTTCTGCGAACACATCTGGTGTCTGAGGTTTTTGGC
ATTGCAATGTACCGCCAGCTGCCTGCTGTGCACCCCATTTTCAAGCTGCTGGTGGCACAC
GTGAGATTCACCATTGCAATCAACACCAAGGCCCGTGAGCAGCTCATCTGCGAGTGTGGC
CTCTTTGACAAGGCCAACGCCACAGGGGGCGGTGGGCACGTGCAGATGGTGCAGAGGGCC
ATGAAGGACCTGACCTATGCCTCCCTGTGCTTTCCCGAGGCCATCAAGGCCCGGGGCATG
GAGAGCAAAGAAGACATCCCCTACTACTTCTACCGGGACGACGGGCTCCTGGTGTGGGAA
GCCATCAGGACGTTCACGGCCGAGGTGGTAGACATCTACTACGAGGGCGACCAGGTGGTG
GAGGAGGACCCGGAGCTGCAGGACTTCGTGAACGATGTCTACGTGTACGGCATGCGGGGC
CGCAAGTCCTCAGGCTTCCCCAAGTCGGTCAAGAGCCGGGAGCAGCTGTCGGAGTACCTG
ACCGTGGTGATCTTCACCGCCTCCGCCCAGCACGCCGCGGTCAACTTCGGCCAGTACGAC
TGGTGCTCCTGGATCCCCAATGCGCCCCCAACCATGCGAGCCCCGCCACCGACTGCCAAG
GGCGTGGTGACCATTGAGCAGATCGTGGACACGCTGCCCGACCGCGGCCGCTCCTGCTGG
CATCTGGGTGCAGTGTGGGCGCTGAGCCAGTTCCAGGAAAACGAGCTGTTCCTGGGCATG
TACCCAGAAGAGCATTTTATCGAGAAGCCTGTGAAGGAAGCCATGGCCCGATTCCGCAAG
AACCTCGAGGCCATTGTCAGCGTGATTGCTGAGCGCAACAAGAAGAAGCAGCTGCCATAT
TACTACTTGTCCCCAGACCGGATTCCGAACAGTGTGGCCATCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01477</identifier>
            <name>PLAT</name>
          </pfam>
          <pfam>
            <identifier>PF00305</identifier>
            <name>Lipoxygenase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytosol</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>dendrite</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear envelope lumen</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear matrix</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nuclear membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>sarcolemma</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonate 5-lipoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>acute inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>leukotriene production involved in inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoxin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipoxygenase pathway</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>positive regulation of vasoconstriction</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to hyperoxia</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to nutrient</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>sensory perception of pain</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="4">
      <id>BE0003768</id>
      <name>Group IIE secretory phospholipase A2</name>
      <organism>Humans</organism>
      <actions>
        <action>unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1991</ref-id>
            <pubmed-id>10592235</pubmed-id>
            <citation>Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="Q9NZK7" source="Swiss-Prot">
        <name>Group IIE secretory phospholipase A2</name>
        <general-function>Phospholipase a2 activity</general-function>
        <specific-function>PA2 catalyzes the calcium-dependent hydrolysis of the 2-acyl groups in 3-sn-phosphoglycerides. Has a preference for arachidonic-containing phospholipids.</specific-function>
        <gene-name>PLA2G2E</gene-name>
        <locus>1p36.13</locus>
        <cellular-location>Secreted</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-19</signal-regions>
        <theoretical-pi>8.28</theoretical-pi>
        <molecular-weight>15988.525</molecular-weight>
        <chromosome-location>1</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:13414</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AF189279</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7108923</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1419</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q9NZK7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PA2GE_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>3.1.1.4</synonym>
          <synonym>GIIE sPLA2</synonym>
          <synonym>Phosphatidylcholine 2-acylhydrolase 2E</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0012632|Group IIE secretory phospholipase A2
MKSPHVLVFLCLLVALVTGNLVQFGVMIEKMTGKSALQYNDYGCYCGIGGSHWPVDQTDW
CCHAHDCCYGRLEKLGCEPKLEKYLFSVSERGIFCAGRTTCQRLTCECDKRAALCFRRNL
GTYNRKYAHYPNKLCTGPTPPC</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012633|Group IIE secretory phospholipase A2 (PLA2G2E)
ATGAAATCTCCCCACGTGCTGGTGTTCCTTTGCCTCCTGGTGGCTCTGGTCACCGGGAAC
CTGGTTCAGTTTGGGGTGATGATCGAGAAGATGACAGGCAAGTCCGCCCTGCAGTACAAC
GACTATGGCTGTTACTGCGGCATCGGTGGCTCCCACTGGCCGGTGGACCAGACTGACTGG
TGCTGCCACGCCCACGACTGCTGCTACGGGCGTCTGGAGAAGCTGGGCTGTGAGCCCAAA
CTGGAAAAGTATCTTTTCTCTGTCAGCGAACGTGGCATTTTCTGCGCCGGCAGGACCACC
TGCCAGCGGCTGACCTGCGAGTGTGACAAGAGGGCTGCCCTCTGCTTTCGCCGCAACCTG
GGCACCTACAACCGCAAATATGCCCATTATCCCAACAAGCTGTGCACCGGGCCCACCCCG
CCCTGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00068</identifier>
            <name>Phospholip_A2_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular region</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>calcium ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>phospholipase A2 activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>glycerophospholipid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>inflammatory response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>lipid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylcholine acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylethanolamine acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylglycerol acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylinositol acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phosphatidylserine acyl-chain remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>phospholipid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
    <target position="5">
      <id>BE0000054</id>
      <name>2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase</name>
      <organism>Mycobacterium tuberculosis</organism>
      <actions>
        <action>unknown</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A1713</ref-id>
            <pubmed-id>17139284</pubmed-id>
            <citation>Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6.</citation>
          </article>
          <article>
            <ref-id>A1715</ref-id>
            <pubmed-id>17016423</pubmed-id>
            <citation>Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P9WNC7" source="Swiss-Prot">
        <name>2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase</name>
        <general-function/>
        <specific-function>2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity</specific-function>
        <gene-name>folK</gene-name>
        <locus/>
        <cellular-location/>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>20731.305</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="83332">Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P9WNC7</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>HPPK_MYCTU</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>2.7.6.3</synonym>
          <synonym>6-hydroxymethyl-7,8-dihydropterin pyrophosphokinase</synonym>
          <synonym>7,8-dihydro-6-hydroxymethylpterin-pyrophosphokinase</synonym>
          <synonym>HPPK</synonym>
          <synonym>PPPK</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051181|2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase
MTRVVLSVGSNLGDRLARLRSVADGLGDALIAASPIYEADPWGGVEQGQFLNAVLIADDP
TCEPREWLRRAQEFERAAGRVRGQRWGPRNLDVDLIACYQTSATEALVEVTARENHLTLP
HPLAHLRAFVLIPWIAVDPTAQLTVAGCPRPVTRLLAELEPADRDSVRLFRPSFDLNSRH
PVSRAPES</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0051182|2-amino-4-hydroxy-6-hydroxymethyldihydropteridine pyrophosphokinase (folK)
ATGACGCGGGTAGTGCTCTCGGTTGGCTCCAACCTGGGTGACCGCCTGGCACGATTGCGG
TCGGTCGCCGACGGTCTCGGCGATGCGTTGATTGCGGCTTCCCCGATATATGAGGCCGAC
CCCTGGGGTGGGGTGGAGCAGGGGCAGTTCCTCAATGCGGTGCTGATCGCCGACGATCCT
ACCTGCGAACCGCGGGAGTGGCTGCGGCGGGCGCAGGAGTTCGAGCGCGCTGCGGGCAGG
GTGCGTGGCCAGCGCTGGGGTCCACGAAATCTCGACGTCGACCTGATCGCCTGCTACCAG
ACCTCGGCCACCGAGGCTCTGGTCGAAGTGACCGCGCGGGAGAACCACCTCACGCTGCCG
CACCCACTGGCGCATCTGCGGGCCTTTGTGTTGATCCCGTGGATTGCCGTCGACCCAACG
GCGCAGCTGACGGTTGCCGGGTGCCCGCGGCCCGTCACGCGACTGCTGGCCGAGCTGGAG
CCCGCCGACCGCGACAGTGTGCGGTTGTTTAGGCCGTCGTTCGATCTGAATAGCAGACAC
CCCGTCAGTCGGGCACCGGAAAGCTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01288</identifier>
            <name>HPPK</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>function</category>
            <description>2-amino-4-hydroxy-6-hydroxymethyldihydropteridine diphosphokinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ATP binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>kinase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>folic acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>tetrahydrofolate biosynthetic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </target>
  </targets>
  <enzymes>
    <enzyme position="6">
      <id>BE0001075</id>
      <name>Myeloperoxidase</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A17776</ref-id>
            <pubmed-id>2563347</pubmed-id>
            <citation>von Ritter C, Grisham MB, Granger DN: Sulfasalazine metabolites and dapsone attenuate formyl-methionyl-leucyl-phenylalanine-induced mucosal injury in rat ileum. Gastroenterology. 1989 Mar;96(3):811-6.</citation>
          </article>
          <article>
            <ref-id>A17777</ref-id>
            <pubmed-id>16614956</pubmed-id>
            <citation>Gorgulu S, Yagci G, Kaymakcioglu N, Ozkara M, Kurt B, Ozcan A, Kaya O, Sadir S, Tufan T: Hyperbaric oxygen enhances the efficiency of 5-aminosalicylic acid in acetic acid-induced colitis in rats. Dig Dis Sci. 2006 Mar;51(3):480-7.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>unknown</known-action>
      <polypeptide id="P05164" source="Swiss-Prot">
        <name>Myeloperoxidase</name>
        <general-function>Peroxidase activity</general-function>
        <specific-function>Part of the host defense system of polymorphonuclear leukocytes. It is responsible for microbicidal activity against a wide range of organisms. In the stimulated PMN, MPO catalyzes the production of hypohalous acids, primarily hypochlorous acid in physiologic situations, and other toxic intermediates that greatly enhance PMN microbicidal activity.</specific-function>
        <gene-name>MPO</gene-name>
        <locus>17q23.1</locus>
        <cellular-location>Lysosome</cellular-location>
        <transmembrane-regions/>
        <signal-regions>1-48</signal-regions>
        <theoretical-pi>9.14</theoretical-pi>
        <molecular-weight>83867.71</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:7218</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>MPO</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>J02694</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>189040</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>2789</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P05164</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>PERM_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.11.2.2</synonym>
          <synonym>MPO</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0002139|Myeloperoxidase
MGVPFFSSLRCMVDLGPCWAGGLTAEMKLLLALAGLLAILATPQPSEGAAPAVLGEVDTS
LVLSSMEEAKQLVDKAYKERRESIKQRLRSGSASPMELLSYFKQPVAATRTAVRAADYLH
VALDLLERKLRSLWRRPFNVTDVLTPAQLNVLSKSSGCAYQDVGVTCPEQDKYRTITGMC
NNRRSPTLGASNRAFVRWLPAEYEDGFSLPYGWTPGVKRNGFPVALARAVSNEIVRFPTD
QLTPDQERSLMFMQWGQLLDHDLDFTPEPAARASFVTGVNCETSCVQQPPCFPLKIPPND
PRIKNQADCIPFFRSCPACPGSNITIRNQINALTSFVDASMVYGSEEPLARNLRNMSNQL
GLLAVNQRFQDNGRALLPFDNLHDDPCLLTNRSARIPCFLAGDTRSSEMPELTSMHTLLL
REHNRLATELKSLNPRWDGERLYQEARKIVGAMVQIITYRDYLPLVLGPTAMRKYLPTYR
SYNDSVDPRIANVFTNAFRYGHTLIQPFMFRLDNRYQPMEPNPRVPLSRVFFASWRVVLE
GGIDPILRGLMATPAKLNRQNQIAVDEIRERLFEQVMRIGLDLPALNMQRSRDHGLPGYN
AWRRFCGLPQPETVGQLGTVLRNLKLARKLMEQYGTPNNIDIWMGGVSEPLKRKGRVGPL
LACIIGTQFRKLRDGDRFWWENEGVFSMQQRQALAQISLPRIICDNTGITTVSKNNIFMS
NSYPRDFVNCSTLPALNLASWREAS</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0016304|Myeloperoxidase (MPO)
ATGGGGGTTCCCTTCTTCTCTTCTCTCAGATGCATGGTGGACTTAGGACCTTGCTGGGCT
GGGGGTCTCACTGCAGAGATGAAGCTGCTTCTGGCCCTAGCAGGGCTCCTGGCCATTCTG
GCCACGCCCCAGCCCTCTGAAGGTGCTGCTCCAGCTGTCCTGGGGGAGGTGGACACCTCG
TTGGTGCTGAGCTCCATGGAGGAGGCCAAGCAGCTGGTGGACAAGGCCTACAAGGAGCGG
CGGGAAAGCATCAAGCAGCGGCTTCGCAGCGGCTCAGCCAGCCCCATGGAACTCCTATCC
TACTTCAAGCAGCCGGTGGCAGCCACCAGGACGGCGGTGAGGGCCGCTGACTACCTGCAC
GTGGCTCTAGACCTGCTGGAGAGGAAGCTGCGGTCCCTGTGGCGAAGGCCATTCAATGTC
ACTGATGTGCTGACGCCCGCCCAGCTGAATGTGTTGTCCAAGTCAAGCGGCTGCGCCTAC
CAGGACGTGGGGGTGACTTGCCCGGAGCAGGACAAATACCGCACCATCACCGGGATGTGC
AACAACAGACGCAGCCCCACGCTGGGGGCCTCCAACCGTGCCTTTGTGCGCTGGCTGCCG
GCGGAGTATGAGGACGGCTTCTCTCTTCCCTACGGCTGGACGCCCGGGGTCAAGCGCAAC
GGCTTCCCGGTGGCTCTGGCTCGCGCGGTCTCCAACGAGATCGTGCGCTTCCCCACTGAT
CAGCTGACTCCGGACCAGGAGCGCTCACTCATGTTCATGCAATGGGGCCAGCTGTTGGAC
CACGACCTCGACTTCACCCCTGAGCCGGCCGCCCGGGCCTCCTTCGTCACTGGCGTCAAC
TGCGAGACCAGCTGCGTTCAGCAGCCGCCCTGCTTCCCGCTCAAGATCCCGCCCAATGAC
CCCCGCATCAAGAACCAAGCCGACTGCATCCCGTTCTTCCGCTCCTGCCCGGCTTGCCCC
GGGAGCAACATCACCATCCGCAACCAGATCAACGCGCTCACTTCCTTCGTGGACGCCAGC
ATGGTGTACGGCAGCGAGGAGCCCCTGGCCAGGAACCTGCGCAACATGTCCAACCAGCTG
GGGCTGCTGGCCGTCAACCAGCGCTTCCAAGACAACGGCCGGGCCCTGCTGCCCTTTGAC
AACCTGCACGATGACCCCTGTCTCCTCACCAACCGCTCAGCGCGCATCCCCTGCTTCCTG
GCAGGGGACACCCGTTCCAGTGAGATGCCCGAGCTCACCTCCATGCACACCCTCTTACTT
CGGGAGCACAACCGGCTGGCCACAGAGCTCAAGAGCCTGAACCCTAGGTGGGATGGGGAG
AGGCTCTACCAGGAAGCCCGGAAGATCGTGGGGGCCATGGTCCAGATCATCACTTACCGG
GACTACCTGCCCCTGGTGCTGGGGCCAACGGCCATGAGGAAGTACCTGCCCACGTACCGT
TCCTACAATGACTCAGTGGACCCACGCATCGCCAACGTCTTCACCAATGCCTTCCGCTAC
GGCCACACCCTCATCCAACCCTTCATGTTCCGCCTGGACAATCGGTACCAGCCCATGGAA
CCCAACCCCCGTGTCCCCCTCAGCAGGGTCTTTTTTGCCTCCTGGAGGGTCGTGCTGGAA
GGTGGCATTGACCCCATCCTCCGGGGCCTCATGGCCACCCCTGCCAAGCTGAATCGTCAG
AACCAAATTGCAGTGGATGAGATCCGGGAGCGATTGTTTGAGCAGGTCATGAGGATTGGG
CTGGACCTGCCTGCTCTGAACATGCAGCGCAGCAGGGACCACGGCCTCCCAGGATACAAT
GCCTGGAGGCGCTTCTGTGGGCTCCCGCAGCCTGAAACTGTGGGCCAGCTGGGCACGGTG
CTGAGGAACCTGAAATTGGCGAGGAAACTGATGGAGCAGTATGGCACGCCCAACAACATC
GACATCTGGATGGGCGGCGTGTCCGAGCCTCTGAAGCGCAAAGGCCGCGTGGGCCCACTC
CTCGCCTGCATCATCGGTACCCAGTTCAGGAAGCTCCGGGATGGTGATCGGTTTTGGTGG
GAGAACGAGGGTGTGTTCAGCATGCAGCAGCGACAGGCCCTGGCCCAGATCTCATTGCCC
CGGATCATCTGCGACAACACAGGCATCACCACCGTGTCTAAGAACAACATCTTCATGTCC
AACTCATATCCCCGGGACTTTGTCAACTGCAGTACACTTCCTGCATTGAACCTGGCTTCC
TGGAGGGAAGCCTCCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF03098</identifier>
            <name>An_peroxidase</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>azurophil granule</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>extracellular space</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>lysosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>nucleus</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>secretory granule</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>chromatin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heparin binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>metal ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>peroxidase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>defense response to fungus</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hydrogen peroxide catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>hypochlorous acid biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>low-density lipoprotein particle remodeling</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of apoptotic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of growth of symbiont in host</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>removal of superoxide radicals</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>respiratory burst involved in defense response</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to oxidative stress</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>response to yeast</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength>unknown</inhibition-strength>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters/>
</drug>